Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNexus Gene Lab (BGLC) Divestments (2021 - 2024)

Historic Divestments for BioNexus Gene Lab (BGLC) over the last 4 years, with Q3 2024 value amounting to $197063.0.

  • BioNexus Gene Lab's Divestments changed N/A to $197063.0 in Q3 2024 from the same period last year, while for Sep 2024 it was $297707.0, marking a year-over-year change of. This contributed to the annual value of $61409.0 for FY2023, which is 4677.63% down from last year.
  • Latest data reveals that BioNexus Gene Lab reported Divestments of $197063.0 as of Q3 2024.
  • In the past 5 years, BioNexus Gene Lab's Divestments registered a high of $197063.0 during Q3 2024, and its lowest value of $7230.0 during Q1 2022.
  • Its 4-year average for Divestments is $42598.6, with a median of $11594.0 in 2022.
  • As far as peak fluctuations go, BioNexus Gene Lab's Divestments skyrocketed by 84468.98% in 2022, and later tumbled by 823.69% in 2023.
  • Over the past 4 years, BioNexus Gene Lab's Divestments (Quarter) stood at $8559.0 in 2021, then soared by 844.69% to $80856.0 in 2022, then tumbled by 86.28% to $11096.0 in 2023, then skyrocketed by 1675.98% to $197063.0 in 2024.
  • Its Divestments stands at $197063.0 for Q3 2024, versus $11096.0 for Q2 2023 and $8692.0 for Q1 2023.